This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) Q1 earnings surpass estimates, while revenues miss the same. The increase in guidance was impressive.
Exelixis (EXEL) Earnings & Revenues Beat Estimates in Q1
by Zacks Equity Research
Exelixis's (EXEL) earnings and revenues beat expectations in the first quarter on strong sales of Cabometyx.
The Zacks Analyst Blog Highlights: FirstEnergy, Synchrony Financial, ExxonMobil, Morgan Stanley and Bristol-Myers
by Zacks Equity Research
The Zacks Analyst Blog Highlights: FirstEnergy, Synchrony Financial, ExxonMobil, Morgan Stanley and Bristol-Myers
Top Research Reports for ExxonMobil, Morgan Stanley & Bristol-Myers
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil (XOM), Morgan Stanley (MS) and Bristol-Myers (BMY).
5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates
by Zacks Equity Research
So far, the going seems good for the drug/biotech sector this earnings season. Let us take a glance at a few other companies, which hold promise to beat on Q1 earnings.
Celgene (CELG) Q1 Earnings Beat Estimates on Revlimid Sales
by Zacks Equity Research
Celgene (CELG) beats on earnings and sales in the first quarter of 2019.
3 Reasons Why Growth Investors Shouldn't Overlook Bristol-Myers (BMY)
by Zacks Equity Research
Bristol-Myers (BMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Bristol-Myers Q1 Earnings Beat, Sales Up on Strong Eliquis
by Zacks Equity Research
Bristol-Myers (BMY) Q1 earnings and sales beat estimates on strong performance of Eliquis and Opdivo.
Bayer (BAYRY) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Bayer (BAYRY) exceeds earnings estimates in the first quarter of 2019 and sales rise year over year.
Exelixis (EXEL) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Exelixis' (EXEL) first-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.
Bristol-Myers Squibb (BMY) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Bristol-Myers (BMY) delivered earnings and revenue surprises of 0.92% and 2.09%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Celgene Corporation (CELG) Q1 Earnings?
by Zacks Equity Research
Investors are looking forward to Revlimid's performance and updates on the impending acquisition agreement with Bristol-Myers, when Celgene Corporation (CELG) reports Q1 results.
Are You Looking for a High-Growth Dividend Stock? Bristol-Myers Squibb (BMY) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Bristol-Myers (BMY) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Bristol-Myers (BMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Top 5 ROE Stocks to Buy on Better-Than-Expected Q1 Earnings
by Supriyo Bose
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
Will Bristol-Myers (BMY) Disappoint This Earnings Season?
by Zacks Equity Research
Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) reports first-quarter results.
Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Bristol-Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal
by Zacks Equity Research
Key highlights of the past week are collaborations and pipeline updates.
Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $46.02, marking a -1.03% move from the previous day.
Bristol-Myers' Shareholders Vote for Celgene Acquisition
by Zacks Equity Research
Bristol-Myers' (BMY) gets a green signal from a majority of its shareholders for the merger with Celgene Corporation.
Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer
by Zacks Equity Research
Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal
by Kinjel Shah
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Seattle Genetics' Adcetris Progresses Well Amid Competition
by Zacks Equity Research
Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
Bull of the Day: Centene (CNC)
by Kevin Cook
Instead of being acquired by managed care giants, CNC goes on the offensive in $17.3 billion bid for WCG
Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed the most recent trading day at $45.98, moving -1.73% from the previous trading session.